Street Insider.com: Regulus therapeutics

February 7, 2016

Regulus Therapeutics Inc. (Nasdaq: RGLS) announced interim results from one of the company’s ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV). Read the full story at Street Insider.com


Fierce Biotech: Regulus shares spike on a high success rate for RG-101 hep C combos

February 7, 2016

Can Regulus still make a splash in the increasingly crowded hepatitis C drug market? The biotech says yes, backing up its case for RG-101 with interim Phase II data that showed its injection pushed a small group of patients to a 97% sustained virologic response rate after only four weeks of combination therapies using some […]


Newsroom America: Study shows promising safety results for anti-aging drug

February 7, 2016

The search for the fountain of youth led to a 2009 discovery that a drug called rapamycin was shown to extend the lifespan of mice. Since that time, studies on the metabolic side effects of rapamycin have made it unclear whether the drug is safe as a long-term treatment. Read the full story at Newsroom […]